Tag Archives: regn

Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK

Praluent, the new cholesterol-busting drug from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), was granted FDA approval Friday, but for a slightly more limited patient pool than some had hoped. Regeneron stock closed down 2.7% to 541.85 on the stock market today, but that was little changed from when shares were halted at 542.01 for much of the afternoon. The FDA announced approval of Praluent for patients with a genetic predisposition to high

Anacor, Regeneron Up On Promising Rash Treatments

Biotechs Anacor Pharmaceuticals (ANAC) and Regeneron Pharmaceuticals (REGN) were both trading up Monday on the potential of their drug candidates for atopic dermatitis (AD). Anacor stock soared 55% to a new high above 131 on the strength of late-stage trial results for its ointment Crisaborole. The company said half the patients with mild to moderate AD — a recurring skin inflammation of unknown origin — were clear or almost clear of the rash

Regeneron, Amgen Downgraded As Biotech Seen Slowing

UBS downgraded Regeneron (REGN) and Amgen (AMGN) and adjusted the price targets on several other biotech stocks Thursday on the grounds that the sector may be in for a slow patch. “Although we still think that biotech will continue to outperform the broader markets and the Health Care SPDR (XLV), we are getting more selective with our price targets and ratings considering fewer near-term catalysts with the power to drive material upward revisions